C34 C61 C50 C67 C00-C14 C18 C22 C25 C95 J44.1 N40 K74.6 K85 K63 D14.3 K50.1 J18.9 D27 N60.2
Conditions
Interventions
Group 1: Study participants with cancer of the lung, prostate, bladder, breast, head and neck, liver, pancreas, ovaries, colon or with leucimia are informed in detail about the course, risks, and bene
Sponsors
Ludwig-Maximilians-Universität München (LMU)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Informed consent, = 18 years, healthy subject, or one of the eligible benign or malignant diseases.
Exclusion criteria
Exclusion criteria: Multiple cancers, any cancer therapy within the last two years, no blood draw possible, participant noncompliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is the accuracy of IMF diagnosis for nine cancer entities, assessed by comparison with all data available to the investigator. A diagnoses is regarded as correct if IMF and clinical routine assessing all available data coincide with regard to the nine tumor entities of interest. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Capability to reproduce or improve the results of the pilot study 2) Capability of IMF to recognize sub-types of tumors and tumor stages 3) Capability of IMF to distinguish between patients with any tumors on the one hand and healthy subjects and patients with benign diseases on the other one 4) Reliability of IMF with regard to sensibility, specificity, PNT and PPT 5) Accuracy of IMF as compared with a conventional FTIR Analyzer 6) Gain additional information on IMFs: defining cancer-independent and cancer-dependent parts of IMFs in longitudinal observations | — |
Countries
Germany
Contacts
Public ContactBianca Höfelschweiger
Fakultät für Physik, Ludwig-Maximilians-Universität München; Urologische Klinik und Poliklinik, LMU Klinikum
Outcome results
None listed